28211499|t|The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis
28211499|a|The outcomes of studies analyzing the prognostic role of CTLA-4 in cancers are controversial. Therefore, the aim of our meta-analysis was to clarify the correlation between CTLA-4 expression and OS in different cancer cases. Relevant literature was searched using PubMed, EMBASE, Web of Science, and the Cochrane Library. The clinicopathological features, hazard ratio (HR) and 95% confidence intervals (CI) were collected from these studies and were analyzed using Stata version 12.0 software. The pooled HR values showed no significant correlation between CTLA-4 expression levels and OS in relation to tumors (HR: 1.24, 95% CI: 0.98-1.56, I2 = 71.7%, P = 0.000). Further subgroup analyses were conducted and categorized by experimental methods, CTLA-4 sources and cancer types. The survey showed a significant correlation (HR: 1.47, 95% CI: 1.14-1.89) between high expression of CTLA-4 and OS in the SNP subgroup, and subgroups analyzing by PCR (HR: 1.50, 95% CI: 1.20-1.86) and flow cytometry (HR: 2.76, 95% CI: 1.49-5.14). In addition, our analysis observed significant differences between patients and controls in in CTLA-4+ CD4+ lymphocytes, sur CTLA-4+ CD4+ lymphocytes, in CTLA-4+ CD8+ lymphocytes, and sur CTLA-4+ CD8+ lymphocytes. Knowledge of the effects of CTLA-4 could potentially be used to effectively guide appropriate prognosis and therapeutic strategies in cancer patients.
28211499	24	56	cytotoxic T-lymphocyte antigen 4	T103	UMLS:C0111208
28211499	60	67	cancers	T038	UMLS:C0006826
28211499	71	88	systematic review	T170	UMLS:C1955832
28211499	93	106	meta-analysis	T062	UMLS:C0920317
28211499	111	119	outcomes	T062	UMLS:C0543472
28211499	131	140	analyzing	T062	UMLS:C0936012
28211499	164	170	CTLA-4	T103	UMLS:C0111208
28211499	174	181	cancers	T038	UMLS:C0006826
28211499	227	240	meta-analysis	T062	UMLS:C0920317
28211499	280	286	CTLA-4	T103	UMLS:C0111208
28211499	318	324	cancer	T038	UMLS:C0006826
28211499	341	351	literature	T170	UMLS:C0023866
28211499	371	377	PubMed	T170	UMLS:C1138432
28211499	379	385	EMBASE	T170	UMLS:C0282574
28211499	387	401	Web of Science	T170	UMLS:C0282574
28211499	411	427	Cochrane Library	T170	UMLS:C0282574
28211499	433	461	clinicopathological features	T091	UMLS:C0030667
28211499	558	566	analyzed	T062	UMLS:C0936012
28211499	573	600	Stata version 12.0 software	T170	UMLS:C0282574
28211499	665	671	CTLA-4	T103	UMLS:C0111208
28211499	712	718	tumors	T038	UMLS:C0027651
28211499	781	789	subgroup	T170	UMLS:C1515021
28211499	790	798	analyses	T062	UMLS:C0936012
28211499	833	853	experimental methods	T062	UMLS:C0871738
28211499	855	861	CTLA-4	T103	UMLS:C0111208
28211499	892	898	survey	T170	UMLS:C0038951
28211499	989	995	CTLA-4	T103	UMLS:C0111208
28211499	1010	1013	SNP	T082	UMLS:C0752046
28211499	1014	1022	subgroup	T170	UMLS:C1515021
28211499	1028	1037	subgroups	T170	UMLS:C1515021
28211499	1038	1047	analyzing	T062	UMLS:C0936012
28211499	1051	1054	PCR	T062	UMLS:C0032520
28211499	1089	1103	flow cytometry	T058	UMLS:C0016263
28211499	1152	1160	analysis	T062	UMLS:C0936012
28211499	1230	1237	CTLA-4+	T103	UMLS:C0111208
28211499	1238	1242	CD4+	T103	UMLS:C0003323
28211499	1243	1254	lymphocytes	T017	UMLS:C0024264
28211499	1260	1267	CTLA-4+	T103	UMLS:C0111208
28211499	1268	1272	CD4+	T103	UMLS:C0003323
28211499	1273	1284	lymphocytes	T017	UMLS:C0024264
28211499	1289	1296	CTLA-4+	T103	UMLS:C0111208
28211499	1297	1301	CD8+	T103	UMLS:C0085358
28211499	1302	1313	lymphocytes	T017	UMLS:C0024264
28211499	1323	1330	CTLA-4+	T103	UMLS:C0111208
28211499	1331	1335	CD8+	T103	UMLS:C0085358
28211499	1336	1347	lymphocytes	T017	UMLS:C0024264
28211499	1377	1383	CTLA-4	T103	UMLS:C0111208
28211499	1443	1452	prognosis	T201	UMLS:C3854082
28211499	1457	1479	therapeutic strategies	T058	UMLS:C0087111
28211499	1483	1489	cancer	T038	UMLS:C0006826